Shares of Genfit S.A. (EPA:GNFT – Get Free Report) fell 0.3% on Monday . The company traded as low as €3.28 ($3.56) and last traded at €3.32 ($3.61). 277,710 shares traded hands during trading, The stock had previously closed at €3.33 ($3.62).
Genfit Stock Performance
The business has a 50-day moving average of €3.53 and a two-hundred day moving average of €4.05.
Genfit Company Profile
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
See Also
- Five stocks we like better than Genfit
- Why is the Ex-Dividend Date Significant to Investors?
- Can TikTok Stock Picks Really Make You Rich?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- The “Quality” Rotation: Back to Basics Investing
- How to Use the MarketBeat Excel Dividend Calculator
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.